腫瘤伴隨診斷市場－全球產業規模、佔有率、趨勢、機會及預測（按產品/服務、技術、疾病類型、最終用途、地區和競爭格局分類，2021-2031年）

全球腫瘤伴隨診斷市場預計將從 2025 年的 32.1 億美元成長到 2031 年的 50.7 億美元，複合年成長率為 7.92%。

這些診斷技術是至關重要的醫療設備，旨在確定患者合格接受特定治療，或識別有發生嚴重不良反應風險的個體。該領域的發展主要得益於全球向個人化醫療的轉變以及需要標靶治療的癌症發生率不斷上升。監管趨勢也支持對生物標記指導治療的日益依賴。根據個人化醫療聯盟預測，2024年將有18種新型個人化藥物獲得FDA核准，約佔新核准治療性分子實體總數的38%。

儘管存在這些積極因素，但該行業在報銷結構方面仍面臨許多挑戰。一個關鍵障礙是診斷編碼系統與支付方的承保政策不匹配，這給產品開發商帶來了財務上的不確定性。不同醫療體系間報銷決策的不一致，不僅使商業化進程複雜化，也限制了病人獲得必要檢測服務的機會。這些經濟障礙不僅延緩了創新診斷技術的整合，也限制了新興腫瘤生物標記的潛在市場，最終阻礙了整個產業的成長。

市場促進因素

全球癌症負擔日益加重，凸顯了廣泛應用伴隨診斷以最佳化治療策略、減少無效處方的必要性。隨著惡性腫瘤發生率的上升，醫療系統越來越需要進行基因組檢測，以確保昂貴的治療方法僅提供給具有特定基因譜且療效顯著的患者。病例數的成長推動了這一需求，成為市場成長的主要動力，迫使實驗室擴大檢測能力。根據美國癌症協會於2024年1月發布的《2024年癌症事實與數據》報告，預計僅在美國就將新增超過200萬例癌症病例，這凸顯了診斷分層工具對於應對這一快速成長的患者群體的緊迫性。

同時，精準腫瘤學的快速普及正在改變臨床工作流程，並推動標靶治療的興起。製藥公司正將重心從廣譜細胞毒性藥物轉向生物標記驅動的藥物，從而在臨床試驗招募和商業性化應用方面都對診斷檢測產生了相互依賴的影響。這種策略調整使得診斷技術通常與治療藥物共同開發，將不斷擴大的診斷市場與藥物研發管線直接連結。例如，Astra Zeneca在2024年2月發布的「2023會計年度全年業績」公告中確認，其臨床研發管線中90%為標靶治療，這顯示整個產業正專注於生物標記依賴性機制。這一趨勢正在推動檢測數量的顯著成長。 Guardant Health報告稱，2024年臨床檢測量較上年成長21%，證實了腫瘤診斷解決方案的應用範圍正在擴大。

市場挑戰

診斷編碼框架與支付方覆蓋政策之間的不匹配構成了重大的財務障礙，直接限制全球腫瘤伴隨診斷市場的成長。由於報銷系統難以跟上快速創新的步伐，開發商面臨收入的不確定性，因此不願投資檢驗新型生物標記。這種經濟上的錯配使得即使是經過臨床檢驗的診斷方法也缺乏明確的支付途徑，迫使臨床檢查室在承擔相關成本和拒絕為合格的患者提供檢測之間做出選擇。這削弱了這些重要工具的商業性永續性，限制了它們在常規臨床實踐中的應用，並阻礙了向個人化醫療的廣泛轉變。

這種經濟負擔對市場滲透率產生了顯著影響，因為它阻礙了臨床實踐。根據國際肺癌研究協會 (IASLC) 2024 年全球生物標記檢測調查，27.2% 的受訪者認為成本是實施必要檢測的主要障礙。這些經濟挑戰有效地限制了潛在市場規模，阻礙了技術的廣泛應用。由於醫療服務提供者需要應對不一致的報銷規定，患者獲得標靶治療的機會被延遲，最終限制了精準腫瘤學領域的整​​體發展潛力。

市場趨勢

市場正經歷著從重複的單一生物標記檢測到多重次世代定序panel的結構性轉變。這項轉變的驅動力在於，需要在保留有限切片檢查組織的同時，提取盡可能多的基因組訊息，以用於複雜的標靶治療。與傳統的順序基因檢測相比，多重panel能夠同時分析數百種基因突變，從而縮短診斷週期，並解決組織耗竭帶來的挑戰。這種產業整合也體現在檢查室的性能指標。根據NeoGenomics於2025年2月發布的“2024年第四季度及全年收益報告”，該公司確認，2024年次世代定序檢測量成長了34%，表明行業正迅速向全面的基因組分析轉型。

同時，人工智慧 (AI) 和機器學習的融合正在改變診斷的準確性。隨著生物資料集呈指數級成長，計算演算法對於解讀多組體學數據以及將基因組學發現與臨床結果關聯至關重要。這種技術融合有助於識別新的生物標記物，從而實現超越傳統病理學能力的患者分層。隨著越來越多的合作夥伴積極尋求數據驅動的洞察，這些演算法解決方案的商業性勢頭正在增強。例如，Tempus AI 在 2025 年 2 月發布的「2024 年第四季及全年」財務報告中指出，其數據服務部門的收入同比成長 44.6%，該部門利用了其人工智慧平台，這凸顯了計算診斷價值的快速成長。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球癌症伴隨診斷市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依產品/服務分類（產品（設備、耗材、軟體）、服務）
  • 依技術（聚合酵素鏈鎖反應（PCR）、次世代定序（NGS）、免疫組織化學（IHC）、原位雜合反應（ISH）/螢光雜合反應（FISH）、其他）
  • 依疾病分類（乳癌、非小細胞肺癌、結腸癌、白血病、黑色素瘤、攝護腺癌、其他）
  • 透過申請（醫院、病理/診斷檢查室、大學附設醫院）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美癌症伴隨診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲癌症伴隨診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區癌症伴隨診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲癌症伴隨診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章 南美洲癌症伴隨診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球腫瘤伴隨診斷市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Agilent Technologies Inc
• Illumina Inc
• QIAGEN NV
• Thermo Fisher Scientific Inc
• F Hoffmann-La Roche AG
• ARUP Laboratories Inc
• Abbott Laboratories Inc
• Myriad Genetics Inc
• bioMerieux SA
• Invivoscribe Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Oncology Companion Diagnostic Market is projected to expand from USD 3.21 Billion in 2025 to USD 5.07 Billion by 2031, registering a compound annual growth rate of 7.92%. These diagnostics act as critical medical devices designed to determine patient eligibility for specific treatments or to identify individuals at risk of severe adverse reactions. The sector's growth is primarily fueled by the global shift toward personalized healthcare and the rising incidence of cancer necessitating targeted interventions. This increasing dependence on biomarker-guided therapy is supported by regulatory trends; according to the Personalized Medicine Coalition, 18 new personalized medicines were approved by the FDA in 2024, accounting for roughly 38 percent of all newly authorized therapeutic molecular entities.

Despite these positive catalysts, the industry faces substantial hurdles related to reimbursement structures. A major obstacle involves the misalignment between diagnostic coding systems and payer coverage policies, which generates financial instability for product developers. Such inconsistent reimbursement decisions across various healthcare systems create complexities in commercialization and restrict patient access to essential testing services. These economic barriers not only delay the integration of innovative diagnostic technologies but also constrain the potential market for emerging oncology biomarkers, thereby hindering the sector's overall growth trajectory.

Market Driver

The increasing global burden of cancer underscores the necessity for widespread companion diagnostic implementation to refine treatment strategies and minimize ineffective prescriptions. As malignancy rates climb, healthcare systems are progressively requiring genomic testing to ensure that expensive therapies are delivered exclusively to patients possessing the specific genetic profiles required for efficacy. This demand, driven by case volume, acts as a primary engine for market growth, compelling laboratories to expand their testing capacities. According to the American Cancer Society's 'Cancer Facts & Figures 2024' report released in January 2024, projections indicate that over 2 million new cancer cases will be diagnosed within the United States alone, highlighting the urgent requirement for diagnostic stratification tools to address this escalating patient load.

Simultaneously, the rapid adoption of precision oncology is transforming clinical workflows and stimulating the increase of targeted therapies. Pharmaceutical companies are pivoting away from broad-spectrum cytotoxic agents toward biomarker-driven medications, establishing a mutual dependency on diagnostic assays for both clinical trial recruitment and commercial delivery. This strategic realignment ensures that diagnostics are often co-developed with therapeutics, linking diagnostic market expansion directly to pharmaceutical pipelines. For instance, AstraZeneca confirmed in its 'Full Year 2023 Results' announcement in February 2024 that 90 percent of its clinical pipeline consists of targeted therapies, demonstrating the industry's focus on biomarker-dependent mechanisms. This trend is resulting in measurable volume increases; Guardant Health reported a 21 percent year-over-year rise in clinical test volume in 2024, confirming the growing application of oncology diagnostic solutions.

Market Challenge

The discrepancy between diagnostic coding frameworks and payer coverage policies represents a significant financial impediment that directly curbs the growth of the global oncology companion diagnostic market. As reimbursement systems struggle to match the pace of rapid technological innovation, developers encounter considerable revenue unpredictability, which deters investment in the validation of new biomarkers. This economic misalignment results in situations where even clinically validated diagnostics frequently lack defined payment channels, compelling clinical laboratories to either absorb the associated costs or refuse testing for eligible patients. As a result, the commercial sustainability of these critical tools is undermined, restricting their availability in routine clinical practice and impeding the wider shift toward personalized medicine.

This financial strain significantly affects market uptake by establishing barriers at the point of care. According to the International Association for the Study of Lung Cancer (IASLC) in its 2024 Global Survey on Biomarker Testing, 27.2 percent of respondents highlighted cost as a major hindrance to implementing essential testing. Such economic challenges effectively limit the total addressable market by precluding widespread adoption. As healthcare providers navigate inconsistent reimbursement rulings, patient access to targeted therapies is postponed, which subsequently suppresses the overall expansion potential of the precision oncology sector.

Market Trends

The market is experiencing a structural transition from iterative single-biomarker assays to multiplex Next-Generation Sequencing panels. This evolution is propelled by the necessity to preserve limited biopsy tissue while extracting maximum genomic information for complex targeted therapies. In contrast to traditional methods that examine genes sequentially, multiplex panels facilitate the simultaneous analysis of hundreds of genetic alterations, thereby shortening diagnostic turnaround times and addressing issues related to tissue exhaustion. This industry consolidation is reflected in laboratory performance metrics; according to the 'Fourth Quarter and Full Year 2024 Results' report by NeoGenomics in February 2025, the company observed a 34 percent growth in its Next-Generation Sequencing test volume during 2024, demonstrating the rapid industrial shift toward comprehensive genomic profiling.

Concurrently, the incorporation of Artificial Intelligence and Machine Learning is transforming diagnostic precision. As biological datasets grow exponentially more complex, computational algorithms have become indispensable for interpreting multi-omics data and linking genomic discoveries with clinical results. This technological convergence aids in the identification of novel biomarkers and enhances patient stratification beyond the capabilities of standard pathology. The commercial momentum of these algorithmic solutions is increasing as partners actively seek data-driven insights. For example, Tempus AI reported in its 'Fourth Quarter and Full Year 2024 Results' announcement in February 2025 that revenue from its Data and Services segment, which leverages AI-enabled platforms, rose by 44.6 percent compared to the prior year, highlighting the escalating value of computational diagnostics.

Key Market Players

• Agilent Technologies Inc
• Illumina Inc
• QIAGEN NV
• Thermo Fisher Scientific Inc
• F Hoffmann-La Roche AG
• ARUP Laboratories Inc
• Abbott Laboratories Inc
• Myriad Genetics Inc
• bioMerieux SA
• Invivoscribe Inc

Report Scope

In this report, the Global Oncology Companion Diagnostic Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oncology Companion Diagnostic Market, By Product & Service

• Product (Instrument, Consumables, Software)
• Service

Oncology Companion Diagnostic Market, By Technology

• Polymerase chain reaction (PCR)
• Next-generation sequencing (NGS)
• Immunohistochemistry (IHC)
• In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
• Others

Oncology Companion Diagnostic Market, By Disease Type

• Breast cancer
• Non-small cell lung cancer
• Colorectal cancer
• Leukemia
• Melanoma
• Prostate cancer
• Others

Oncology Companion Diagnostic Market, By End Use

• Hospitals
• Pathology/Diagnostic laboratory
• Academic medical center

Oncology Companion Diagnostic Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Oncology Companion Diagnostic Market.

Available Customizations:

Global Oncology Companion Diagnostic Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oncology Companion Diagnostic Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product & Service (Product (Instrument, Consumables, Software), Service)
  • 5.2.2. By Technology (Polymerase chain reaction (PCR), Next-generation sequencing (NGS), Immunohistochemistry (IHC), In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH), Others)
  • 5.2.3. By Disease Type (Breast cancer, Non-small cell lung cancer, Colorectal cancer, Leukemia, Melanoma, Prostate cancer, Others)
  • 5.2.4. By End Use (Hospitals, Pathology/Diagnostic laboratory, Academic medical center)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Oncology Companion Diagnostic Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product & Service
  • 6.2.2. By Technology
  • 6.2.3. By Disease Type
  • 6.2.4. By End Use
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Oncology Companion Diagnostic Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product & Service
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Disease Type
      • 6.3.1.2.4. By End Use
  • 6.3.2. Canada Oncology Companion Diagnostic Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product & Service
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Disease Type
      • 6.3.2.2.4. By End Use
  • 6.3.3. Mexico Oncology Companion Diagnostic Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product & Service
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Disease Type
      • 6.3.3.2.4. By End Use

7. Europe Oncology Companion Diagnostic Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product & Service
  • 7.2.2. By Technology
  • 7.2.3. By Disease Type
  • 7.2.4. By End Use
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Oncology Companion Diagnostic Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product & Service
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Disease Type
      • 7.3.1.2.4. By End Use
  • 7.3.2. France Oncology Companion Diagnostic Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product & Service
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Disease Type
      • 7.3.2.2.4. By End Use
  • 7.3.3. United Kingdom Oncology Companion Diagnostic Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product & Service
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Disease Type
      • 7.3.3.2.4. By End Use
  • 7.3.4. Italy Oncology Companion Diagnostic Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product & Service
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Disease Type
      • 7.3.4.2.4. By End Use
  • 7.3.5. Spain Oncology Companion Diagnostic Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product & Service
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Disease Type
      • 7.3.5.2.4. By End Use

8. Asia Pacific Oncology Companion Diagnostic Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product & Service
  • 8.2.2. By Technology
  • 8.2.3. By Disease Type
  • 8.2.4. By End Use
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Oncology Companion Diagnostic Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product & Service
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Disease Type
      • 8.3.1.2.4. By End Use
  • 8.3.2. India Oncology Companion Diagnostic Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product & Service
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Disease Type
      • 8.3.2.2.4. By End Use
  • 8.3.3. Japan Oncology Companion Diagnostic Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product & Service
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Disease Type
      • 8.3.3.2.4. By End Use
  • 8.3.4. South Korea Oncology Companion Diagnostic Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product & Service
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Disease Type
      • 8.3.4.2.4. By End Use
  • 8.3.5. Australia Oncology Companion Diagnostic Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product & Service
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Disease Type
      • 8.3.5.2.4. By End Use

9. Middle East & Africa Oncology Companion Diagnostic Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product & Service
  • 9.2.2. By Technology
  • 9.2.3. By Disease Type
  • 9.2.4. By End Use
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Oncology Companion Diagnostic Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product & Service
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Disease Type
      • 9.3.1.2.4. By End Use
  • 9.3.2. UAE Oncology Companion Diagnostic Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product & Service
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Disease Type
      • 9.3.2.2.4. By End Use
  • 9.3.3. South Africa Oncology Companion Diagnostic Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product & Service
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Disease Type
      • 9.3.3.2.4. By End Use

10. South America Oncology Companion Diagnostic Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product & Service
  • 10.2.2. By Technology
  • 10.2.3. By Disease Type
  • 10.2.4. By End Use
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Oncology Companion Diagnostic Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product & Service
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Disease Type
      • 10.3.1.2.4. By End Use
  • 10.3.2. Colombia Oncology Companion Diagnostic Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product & Service
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Disease Type
      • 10.3.2.2.4. By End Use
  • 10.3.3. Argentina Oncology Companion Diagnostic Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product & Service
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Disease Type
      • 10.3.3.2.4. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Oncology Companion Diagnostic Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Agilent Technologies Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Illumina Inc
• 15.3. QIAGEN NV
• 15.4. Thermo Fisher Scientific Inc
• 15.5. F Hoffmann-La Roche AG
• 15.6. ARUP Laboratories Inc
• 15.7. Abbott Laboratories Inc
• 15.8. Myriad Genetics Inc
• 15.9. bioMerieux SA
• 15.10. Invivoscribe Inc

16. Strategic Recommendations

17. About Us & Disclaimer